$CLDX Should Investors Buy Celldex Therapeutics, Inc. (NASDAQ:CLDX)?
by Clinton Staff Writer — April 1, 2016
Research brokerage firms on Wall Street employ an army of analysts which dedicate the majority of their time analyzing stocks in their coverage universe. They issue Buy, Sell and Hold recommendations as well as earnings estimates and guidance. Out of the 8 analysts covering shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX), 5 rate it a “Strong Buy”, 0 rate it a “Buy”, 5 are advising to Hold the shares and 0 are saying “Sell”. Each recommendation can be mapped to an integer using a 1 to 5 scale. Taking the average of the numerical ratings, the stock has a consensus recommendation of 2. This is based on a 1 to 5 scale where 1 is equivalent to a Strong Buy rating and 5 a Strong Sell.
Investors will be looking ahead to the company’s earnings report with is scheduled to go out on or about 2016-05-04. The Wall Street consensus is saying that the firm will report earnings of $-0.34 per share for the quarter. Analysts often update their models several times during the quarter leading up to the earnings period. The direction of the sentiment is an important indicator of where the Street sees the stock headed. In comparing to the same quarter last year, the firm posted earnings per share of $-0.33. Most recently the firm posted quarter earnings of $-0.33 against the Zack’s consensus estimate of $-0.34. This represents a surprise factor of 2.94% or a numerical difference of $0.01.
The covering sell-side analysts also issue 12-month price targets on the stocks they cover. The 8 analysts weighing in on shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) have a consensus target of $8.75 on the stock. The standard deviation of all the estimates stands at $6.777 with the lowest being $4 and the highest sitting at $24.
This article is for informational purposes only. The author does not have any position in the stock mentioned and in no way is recommending to Buy or Sell.
Celldex Therapeutics, Inc. - Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with Mar
by Clinton Staff Writer — April 1, 2016
Research brokerage firms on Wall Street employ an army of analysts which dedicate the majority of their time analyzing stocks in their coverage universe. They issue Buy, Sell and Hold recommendations as well as earnings estimates and guidance. Out of the 8 analysts covering shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX), 5 rate it a “Strong Buy”, 0 rate it a “Buy”, 5 are advising to Hold the shares and 0 are saying “Sell”. Each recommendation can be mapped to an integer using a 1 to 5 scale. Taking the average of the numerical ratings, the stock has a consensus recommendation of 2. This is based on a 1 to 5 scale where 1 is equivalent to a Strong Buy rating and 5 a Strong Sell.
Investors will be looking ahead to the company’s earnings report with is scheduled to go out on or about 2016-05-04. The Wall Street consensus is saying that the firm will report earnings of $-0.34 per share for the quarter. Analysts often update their models several times during the quarter leading up to the earnings period. The direction of the sentiment is an important indicator of where the Street sees the stock headed. In comparing to the same quarter last year, the firm posted earnings per share of $-0.33. Most recently the firm posted quarter earnings of $-0.33 against the Zack’s consensus estimate of $-0.34. This represents a surprise factor of 2.94% or a numerical difference of $0.01.
The covering sell-side analysts also issue 12-month price targets on the stocks they cover. The 8 analysts weighing in on shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) have a consensus target of $8.75 on the stock. The standard deviation of all the estimates stands at $6.777 with the lowest being $4 and the highest sitting at $24.
This article is for informational purposes only. The author does not have any position in the stock mentioned and in no way is recommending to Buy or Sell.
Celldex Therapeutics, Inc. - Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with Mar
1
I'm in it to win it!
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
